YOLFTbeta
Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX · ST · Healthcare / Biotechnology

11.20SEK+0.08 (+0.72%)

Price History

Full chart

Market Stats

Previous Close11.12
Open11.10
Day Range11.10 – 11.20
52-Week Range3.63 – 9.68
Volume2.23M
Market Cap4.27B
P/E (TTM)0.00
Forward P/E19.68
EPS-1.00
Dividend Yield0.00%
Beta0.81
50-Day Avg7.46
200-Day Avg6.00

About

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Nicklas Westerholm
  • Employees56
  • HeadquartersKlara Norra Kyrkogata 26, Stockholm, Sweden, 111 22, Sweden
  • Websitehttps://www.egetis.com

Leadership

  • Mr. Nicklas WesterholmChief Executive Officer · b. 1976
  • Mr. Torsten AlménFounder
  • Dr. Ingemar Lundström Ph.D.Founder · b. 1943
  • Dr. Louis Joseph Ignarro Ph.D.Founder · b. 1942
  • Associate Prof. Heidi BrurokFounder
  • Dr. Rob TowartFounder
  • Dr. Yilmaz Mahshid Ph.D.Chief Financial Officer · b. 1979
  • Dr. Katayoun Welin-Berger Ph.D.Vice President of Operations · b. 1968
  • Dr. Karl Hard Ph.D.Head of Investor Relations & Business Development · b. 1962
  • Ms. Laetitia Szaller L.L.M.General Counsel and Head of Compliance & ESG

Financials

Income Statement

Currency: SEK2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--2.67K------13.59M28.21M82.56M40.66M38.24M22.50M57.60M46.10M62.40M
Growth (%)----------+107.66%+192.66%-50.75%-5.95%-41.17%+156.00%-19.97%+35.36%
Cost of Revenue-509.27K-732.56K--18.60M10.56M29.46M26.09M19.51M74.20M83.86M112.24M185.17M96.53M142.60M204.50M11.60M50.00M
Gross Profit509.27K732.56K2.67K--18.60M-10.56M-29.46M-26.09M-19.51M-60.61M-55.64M-29.68M-144.51M-58.28M-120.10M-146.90M34.50M12.40M
Gross Margin--100.00%-------446.17%-197.24%-35.95%-355.39%-152.40%-533.78%-255.03%74.84%19.87%
Operating Expense1.07M2.08M3.80M-16.71M15.53M19.11M17.93M18.85M27.48M36.87M37.00M33.89M47.40M78.00M177.90M363.90M359.30M
Operating Income-561.19K-1.35M-3.80M-34.23M-35.31M-26.08M-48.57M-44.03M-38.36M-88.10M-92.51M-66.68M-178.40M-105.68M-198.10M-324.80M-329.40M-346.90M
Operating Margin---142557.35%-------648.49%-327.94%-80.76%-438.73%-276.34%-880.44%-563.89%-714.53%-555.93%
EBITDA-557.14K-1.34M-3.80M-16.11M-33.85M-26.19M-48.61M-44.13M-38.22M-87.94M-85.00M-61.20M-177.63M-101.90M-191.00M-319.10M-317.30M-343.20M
EBITDA Margin---142478.39%-------647.29%-301.31%-74.13%-436.84%-266.45%-848.89%-553.99%-688.29%-550.00%
Net Income-559.07K-1.35M-3.80M-33.25M-33.86M-25.55M-48.42M-43.84M-38.22M-87.94M-85.00M-61.43M-179.12M-104.73M-189.50M-326.90M-343.60M-342.50M
Net Income Margin---142559.04%-------647.29%-301.31%-74.40%-440.51%-273.85%-842.22%-567.53%-745.34%-548.88%
R&D-------26.09M19.51M74.20M83.86M112.24M183.28M88.67M136.30M194.00M146.20M158.30M
R&D as % of Total Revenue---------546.17%297.24%135.95%450.73%231.86%605.78%336.81%317.14%253.69%
Interest Expense005038.18K1.00K1.00K147.00K10.00K001.00K7.00K1.00K200.00K100.00K4.10M25.90M22.70M
Interest Expense % of Total Revenue--1.88%------0.00%0.00%0.01%0.00%0.52%0.44%7.12%56.18%36.38%

Balance Sheet

Currency: SEK2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.37M5.91M8.49M91.42M60.46M51.01M103.47M52.36M396.44M315.37M242.04M270.07M893.97M569.27M561.10M760.20M792.30M639.10M
Total Liabilities323.55K273.98K1.50M3.89M6.52M4.06M12.81M4.33M6.87M11.66M22.68M25.20M264.34M42.23M54.90M214.60M299.40M300.40M
Total Equity5.05M5.64M6.99M87.53M53.94M46.95M90.66M48.03M389.56M303.71M219.36M244.88M629.63M527.04M506.20M545.60M492.80M338.70M
Cash717.29K380.44K568.27K90.55M58.81M49.30M100.04M50.36M394.00M309.53M229.88M255.10M287.85M143.97M127.70M303.30M351.00M215.80M
Total Debt-----------117.00K4.67M4.20M2.70M113.00M117.40M90.60M
Net Debt-717.29K-380.44K-568.27K-90.55M-58.81M-49.30M-100.04M-50.36M-394.00M-309.53M-229.88M-254.98M-283.18M-139.76M-125.00M-190.30M-233.60M-125.20M

Cash Flow

Currency: SEK2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.72M-14.40M-31.96M-28.07M-41.38M-51.15M-36.12M-86.55M-80.31M-62.64M-134.64M-130.11M-173.50M-278.40M-227.90M-267.10M
Investing Cash Flow-2.24M-9.41M216.00K-----59.54M-59.54M-59.54M-59.54M-5.96M-1.70M-100.00K-1.20M-2.80M
Financing Cash Flow5.15M113.79M-18.56M92.13M1.21M379.75M2.08M655.00K86.72M228.41M-8.90M155.70M458.90M270.90M140.00M
Capital Expenditure2.24M9.41M0000024.00K24.00K24.00K24.00K172.00K0001.50M
Free Cash Flow-4.96M-23.81M-31.96M-28.07M-41.38M-51.15M-36.12M-86.55M-80.31M-62.64M-134.66M-130.28M-173.50M-278.40M-227.90M-268.60M
FCF to OCF182.62%165.39%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.02%100.13%100.00%100.00%100.00%100.56%

Earnings

Report DateJun 30, 2011Sep 30, 2011Dec 31, 2011May 30, 2012Aug 29, 2012Oct 26, 2012Feb 21, 2013May 29, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 28, 2014Aug 28, 2014Oct 24, 2014Feb 17, 2015Apr 21, 2015Aug 18, 2015Oct 20, 2015Feb 29, 2016Apr 29, 2016Aug 25, 2016Oct 20, 2016Feb 24, 2017Apr 25, 2017Aug 30, 2017Oct 20, 2017Feb 22, 2018Apr 24, 2018Aug 22, 2018Oct 23, 2018Feb 21, 2019May 6, 2019Aug 21, 2019Oct 22, 2019Feb 18, 2020Apr 22, 2020Aug 20, 2020Nov 11, 2020Feb 17, 2021Apr 22, 2021Aug 19, 2021Nov 4, 2021Feb 17, 2022Apr 26, 2022Aug 19, 2022Nov 8, 2022Feb 22, 2023Apr 26, 2023Aug 22, 2023Nov 8, 2023Feb 22, 2024May 3, 2024Aug 22, 2024Nov 8, 2024Feb 20, 2025Apr 30, 2025Aug 21, 2025Nov 25, 2025Feb 26, 2026Apr 29, 2026Aug 20, 2026Nov 6, 2026
EPS Estimate------0.47-0.42---------------------------0.81-0.70-0.85-0.75-0.28--0.24-0.25-0.24-0.23-0.17-0.22-0.22-0.21-0.35-0.28-0.26-0.30-0.31-0.30-0.32-0.23-0.23--0.20-0.21-0.18-0.17-0.19
EPS Actual-0.16-0.10-1.40-0.38-0.43-0.28-0.40-0.32-0.24-0.18-0.26-0.26-0.47-0.42-0.66-0.38-0.36-0.36-0.28-0.22-0.38-0.25-0.31-0.23-0.30-0.51-0.60-0.29-0.52-0.35-0.410.43-0.52-0.60-0.39-0.80-0.70-0.50-0.64-0.10-0.20-0.10-0.20-0.18-0.20-0.30-0.40-0.30-0.30-0.30-0.30-0.30-0.20-0.30-0.30-0.20-0.22-0.20-0.30-0.20-0.20-
Surprise-----40.43%4.76%--------------------------25.93%44.29%5.88%6.67%-78.57%-58.33%20.00%58.33%13.04%-5.88%9.09%-36.36%-90.48%14.29%-7.14%-15.38%0.00%3.23%33.33%6.25%-31.00%13.04%-0.00%-42.86%-11.11%-17.65%-
Timing-----Pre-marketPre-market-----After-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap4.27B
Enterprise Value3.31B
Trailing P/E0.00
Forward P/E19.68
Price / Sales64.67
Price / Book7.53
EPS-1.00
Book Value1.04
Revenue (TTM)66.00M
Gross Profit (TTM)11.00M
EBITDA-381.00M
Profit Margin0.00%
Operating Margin-627.59%
Return on Equity-96.92%
Return on Assets-34.38%
Shares Outstanding464.97M
Shares Float240.07M
Beta0.81
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%